US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

41.77

+0.08000.19%

Post-market: 41.900.1300+0.31%19:30 EDT

Volume:61.84K

Turnover:2.58M

Market Cap:284.04M

PE:- -

High:41.83

Open:41.75

Low:41.21

Close:41.69

52wk High:41.86

52wk Low:22.38

Shares:6.80M

Float Shares:6.80M

Volume Ratio:0.33

T/O Rate:0.91%

Dividend:0.28

Dividend Rate:0.67%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Moderna Set for 3 Near-Term INT Data Readouts, UBS Says

MT Newswires Live

Twist Bioscience initiated with a Sell at BWS Financial

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

UBS Initiates Coverage on Twist Bioscience With Neutral Rating, $144 Price Target

MT Newswires Live

ProQR Therapeutics doses first participant in AX-0811 clinical trial

Twist Bioscience CEO, CFO to Speak at Baird Global Healthcare Conference Fireside Chat

Bayer initiates Phase II study of BAY 3670549 in patients with AFib

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Evotec initiates clinical trial evaluating JST-018

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Moderately bullish activity in Moderna with shares down 1.79%

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send?

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Ascletis Starts U.S. Phase I Trial of Oral Obesity Drug ASC36

Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/IDNA/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":41.77,"timestamp":1790366400000,"preClose":41.69,"halted":0,"volume":61840,"hourTrading":{"tag":"盘后","latestPrice":41.9,"preClose":41.77,"latestTime":"19:30 EDT","volume":2623,"amount":111352.0686,"timestamp":1790379004993,"change":0.13,"changeRate":0.003112,"amplitude":0.029447},"delay":0,"changeRate":0.0019189254017751357,"floatShares":6800000,"shares":6800000,"eps":0,"marketStatus":"Market Closed","change":0.08,"latestTime":"09-25 16:00:00 EDT","open":41.75,"high":41.828,"low":41.205,"amount":2581118.116,"amplitude":0.014944,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":41.69,"sharesOutstanding":5100000,"nav":41.521308,"aum":284420959.8,"dividendRate":0.006696,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":41.5,"preClose":41.69,"latestTime":"07:12 EDT","volume":2,"amount":83,"timestamp":1790334777796,"change":-0.19,"changeRate":-0.004557,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":41.9,"preClose":41.77,"latestTime":"19:30 EDT","volume":2623,"amount":111352.0686,"timestamp":1790379004993,"change":0.13,"changeRate":0.003112,"amplitude":0.029447},"volumeRatio":0.33317062737783076,"impliedVol":0.1005,"impliedVolPercentile":0.1793},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6800000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.33317062737783076,"shares":6800000,"dividePrice":0.2797,"high":41.828,"amplitude":0.014944,"preClose":41.69,"low":41.205,"week52Low":22.375,"pbRate":"--","week52High":41.86,"institutionHeld":0,"latestPrice":41.77,"eps":0,"divideRate":0.006696,"volume":61840,"delay":0,"ttmEps":0,"open":41.75,"prevYearClose":26.19,"prevWeekClose":39.83,"prevMonthClose":39.26,"prevQuarterClose":33.75,"fiveDayClose":39.83,"twentyDayClose":40.6,"sixtyDayClose":33.61},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666311265","title":"Moderna Set for 3 Near-Term INT Data Readouts, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666311265","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666311265?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:58","pubTimestamp":1788969505,"startTime":"0","endTime":"0","summary":"Moderna  is set for three data readouts on its individualized neoantigen therapies, or INT, in the near term, serving as potential stock catalysts for the company, UBS Securities said in a Tuesday note.The next major catalyst is the release of phase 3 data on melanoma at an international conference this fall, investors awaiting efficacy on recurrence-free survival and distant metastasis-free survival, the brokerage said.Likely to follow is the phase 2 data on either renal cell carcinoma or muscle-invasive bladder cancer, potentially in 2027, according to UBS. The next readout is probably a phase 3 update on adjuvant non-small cell lung cancer, the investment firm added.UBS has a neutral rating and $150 price target on Moderna.Price: 137.50, Change: -2.83, Percent Change: -2.02","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WDNA","BK4139","MRNA","IDNA","BK4501","BK4534","BK4532","BK4585","BK4568","MRNY","GNOM","BK4548","BK4533","BK4588","LGHT","BK4551","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666536557","title":"Twist Bioscience initiated with a Sell at BWS Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666536557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666536557?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:30","pubTimestamp":1788960619,"startTime":"0","endTime":"0","summary":"BWS Financial initiated coverage of Twist Bioscience (TWST) with a Sell rating and $45 price target Twist’s stock surge in August, driven by Anthro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/twist-bioscience-initiated-with-a-sell-at-bws-financial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/twist-bioscience-initiated-with-a-sell-at-bws-financial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","TWST","BK4139","GNOM","BK4588","IDNA","WDNA","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666907533","title":"IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666907533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666907533?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:30","pubTimestamp":1788957000,"startTime":"0","endTime":"0","summary":"Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept.  09, 2026 (GLOBE NEWS","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358657/0/en/imunon-announces-full-agenda-and-speaker-lineup-ahead-of-2026-r-d-day-highlighting-imnn-001-clinical-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MEDX","IMNN","NVIB","BK4097","LU2065732104.USD","GDOC","PRGS","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538213","title":"UBS Initiates Coverage on Twist Bioscience With Neutral Rating, $144 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538213","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538213?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:17","pubTimestamp":1788956271,"startTime":"0","endTime":"0","summary":"Twist Bioscience (TWST) has an average rating of buy and mean price target of $87.56, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TWST","WDNA","BK4588","IDNA","BK4585","GNOM","BK4139","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538091","title":"ProQR Therapeutics doses first participant in AX-0811 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538091?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:15","pubTimestamp":1788956125,"startTime":"0","endTime":"0","summary":"ProQR Therapeutics (PRQR) announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. Publi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRQR","BK4139","AX","IDNA","GDOC","HYLG","BK4195","LU2360107671.USD","NVIB","LENZ","MEDX","LU1861217088.USD","BK4539","BK4007","LU1861220207.SGD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538631","title":"Twist Bioscience CEO, CFO to Speak at Baird Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538631?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:03","pubTimestamp":1788955397,"startTime":"0","endTime":"0","summary":"Twist Bioscience CEO, CFO to speak at Baird Global Healthcare Conference fireside chatTwist Bioscience will join the Baird 2026 Global Healthcare Conference in New York City on Sept. 15, 2026.CEO Emil","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL63nZ4z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","TWST","ARKG","BK4139","BK4588","IDNA","BK4585","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538313","title":"Bayer initiates Phase II study of BAY 3670549 in patients with AFib","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538313","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538313?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:45","pubTimestamp":1788954315,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced the initiation of a global Phase II clinical trial evaluating BAY 3670549, an investigational highly selective G-protein-co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-initiates-phase-ii-study-of-bay-3670549-in-patients-with-afib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-initiates-phase-ii-study-of-bay-3670549-in-patients-with-afib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","IDNA","NVIB","GDOC","MEDX","BAY","BAYRY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666769587","title":"Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666769587","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666769587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952232,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Collegium Pharmaceutical (COLL), Revolution Medicine...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","IE00BJT1NW94.SGD","NTLA","CANC","LU1861558580.USD","IE0009355771.USD","BK4007","LU0128526141.USD","LU0029874061.USD","BK4585","HCSG","XBI","BK4139","IE00BFTCPJ56.SGD","BK4535","RVMD","BK4137","COLL","LU0889565916.HKD","XLV","IDNA","IE00BJJMRZ35.SGD","BK4556","BK4588","LABU","BK4581","IE0009354923.USD","BBH","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PTH","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666858794","title":"Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666858794","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666858794?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358477/24675/en/fate-therapeutics-announces-encore-clinical-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-at-the-ccr-west-2026-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077","IDNA","BMED","NVIB","FATE","HYLG","BK4139","CCR","GDOC","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587949","title":"Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587949","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587949?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358458/0/en/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HYLG","GDOC","IDNA","NVIB","ARB","LABU","MEDX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558799","title":"Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558799?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358479/0/en/satellos-announces-forazapadin-as-assigned-international-nonproprietary-name-for-lead-drug-candidate-sat-3247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IDNA","BK4181","BK4218","SAT","MEDX","HYLG","INN","GDOC","DBB","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589922","title":"Evotec initiates clinical trial evaluating JST-018","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589922?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:15","pubTimestamp":1788945324,"startTime":"0","endTime":"0","summary":"Evotec (EVO) announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","GDOC","IDNA","MEDX","EVO","HYLG","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FHLC","FXH","IBRN","WDNA","GSKH","PBPH","APXH","IBBJ","JDOC","AZNH","XPH","IDNA","CURE","IBB","FTXH","HYLG","GNOM","MDTX","BIB","MEDI","IBBQ","BBP","SBIO","MNTL","SURI","BBH","JHMH","RSPH","FBT","TBXU","GPCR","LFSC","PSCH","PSIL","IEIH","HRTS","CNCR","CANC","GNMX","LLYX","PTH","MEDX","GDOC","SYNB","MRNY","PINK","PBE","PJP","BME","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372326","title":"Moderately bullish activity in Moderna with shares down 1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372326?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:20","pubTimestamp":1788891611,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Moderna (MRNA), with shares down $2.60 near $142.95. Options volume relatively light with 44k contracts traded and c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-down-1-79-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-down-1-79-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4534","BK4551","BK4501","IDNA","LGHT","MRNY","BK4585","GNOM","MRNA","MRNX","WDNA","BK4548","BK4588","BK4568","BK4532","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372878","title":"Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send?","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372878","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372878?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:15","pubTimestamp":1788891334,"startTime":"0","endTime":"0","summary":"• Vertex shares faced volatility and profit-taking after rallying near their 52-week high.\n• The Crinetics acquisition integration will not be non-GAAP accretive until 2029.\n• Technical indicators show a neutral MACD, neutral RSI, and oversold Williams %R.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262156625-market-movers-vrtx-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","IE00B19Z3B42.SGD","IDNA","IE00BFTCPJ56.SGD","LU1093756325.SGD","SG9999001176.USD","LU2462157665.USD","LU2456880835.USD","BK4567","LU2468319806.SGD","LU1035775433.USD","BIB","BBH","LU0256863811.USD","BK4585","PBE","LU2362541273.HKD","BK4139","LU1585245621.USD","LU0889565916.HKD","IE00B19Z9P08.USD","GNMX","IE00B19Z9Z06.USD","LU1430594728.SGD","LU2362541513.USD","IE00BJT1NW94.SGD","LU1069344957.HKD","LU1674673691.USD","LU2236285917.USD","LU2237438978.USD","IE0009355771.USD","LU0823416689.USD","IE00B2B36J28.USD","IE0002141913.USD","LU1093756168.USD","TBXU","IBB","IE00B4R5TH58.HKD","IE00B19Z3581.USD","VRTX","SGXZ57979304.SGD","IBBQ","IE00BZ9MQY76.HKD","LU1778281490.HKD","IE00B894F039.SGD","LU0320765992.SGD","LU0417517546.SGD","BK4533","BK4588","LU2362540622.SGD","LU2417539215.USD","LU0289739699.SGD","LU1674673428.USD","LU2089984988.USD","IE0002270589.USD","LU0234570918.USD","LU0079474960.USD","LU0432979614.USD","LU2324357040.USD","IE00BJJMRZ35.SGD","SG9999013999.USD","SG9999001176.SGD","LU0058720904.USD","LU0061475181.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","IBRN","PSIL","WDNA","MDTX","AZNH","JDOC","FHLC","IBBJ","IDNA","MRNY","APXH","IBB","GSKH","FTXH","BIB","MNTL","GPCR","PBE","SURI","GNOM","PJP","SYNB","BME","GDOC","BBP","JHMH","LENZ","GNMX","PTH","NVIB","MEDI","CURE","HYLG","XPH","LLYX","TBXU","BBH","CNCR","FXH","HRTS","PINK","PSCH","LFSC","PBPH","RSPH","FBT","SBIO","CANC","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378444","title":"PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378444","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378444?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:30","pubTimestamp":1788870600,"startTime":"0","endTime":"0","summary":"Dr. Soon-Shiong will Join PDS Biotech’s Board of Directors PDS Biotech Plans toProgressDevelopment of PDS0301ImmunocytokineinSolidTumors PRINCETON, N.J., Sept.  08, 2026 (GLOBE NEWSWIRE) -- PDS Biotec","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357657/37149/en/pds-biotech-announces-up-to-22-55-million-financing-led-by-dr-patrick-soon-shiong-founder-of-nantworks.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4113","MSS","BK4585","PATK","XBI","BK4124","NCI","BK4588","BK4202","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732264","title":"Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732264","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732264?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:01","pubTimestamp":1788865260,"startTime":"0","endTime":"0","summary":"Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical developmentAppointment strengthens executive leadership team as Editas","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","AAP","BK4139","WDNA","HELX","IE00B7SZL793.SGD","ASCI","SYNB","GNMX","IDNA","BK4214","BK4588","BK4556","IE0031619046.USD","IE00B19Z4B17.USD","BK4585","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321700","title":"Ascletis Starts U.S. Phase I Trial of Oral Obesity Drug ASC36","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321700?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862087,"startTime":"0","endTime":"0","summary":"Ascletis Pharma, Inc. ( ($HK:1672) ) has issued an announcement. Ascletis Pharma Inc. has initiated a Phase I clinical trial in the U.S. for ASC36 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascletis-starts-u-s-phase-i-trial-of-oral-obesity-drug-asc36?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascletis-starts-u-s-phase-i-trial-of-oral-obesity-drug-asc36?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","IDNA","MEDX","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665703321","title":"Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665703321","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665703321?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:05","pubTimestamp":1788861944,"startTime":"0","endTime":"0","summary":"Roivant announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-announces-positive-results-from-phase-2-phocus-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-announces-positive-results-from-phase-2-phocus-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","GDOC","IDNA","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}